Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Loperamide ECG Effects Study
NCT04225078Phase 1Completed
- Sponsor
- Janssen Pharmaceutical
- Start
- Jan 2020
- Primary completion
- Dec 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of loperamide in diarrhea (4 arms), sponsored by Janssen Pharmaceutical. Primary endpoints: Change from Baseline in QT Interval Corrected for Heart Rate (QTc) Intervals for Loperamide up to 9 weeks, Percentage of Participants with Change from Baseline in T-wave Morphology up to 9 weeks and 1 more. Started Jan 2020; status: completed.
02
Drugs
loperamide
03
Conditions
diarrhea
Beyond the preview
Go deeper on NCT04225078.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04225078.